-

Ochre Bio to Participate in Upcoming Global Industry Conferences

OXFORD, England--(BUSINESS WIRE)--Ochre Bio, an innovator in chronic liver disease medicine development, has announced its participation in upcoming investor and industry conferences, sharing expert perspectives and insights across liver disease and RNA therapeutics, building and scaling startups, and the future of medicine.

BioEquity Europe
Location: Dublin, Ireland

Date/Time: May 15, 12.50 BST
Talk title: Ochre Bio – Pioneering novel RNAi therapeutics for liver diseases
Presenter: Jack O’Meara – CEO & Co-Founder, Ochre Bio

The session recording will be available to watch for 30 days after the event. Please register for the event here

UK BioIndustry Association - Startup Festival
Location: London

Date/Time: May 25, 14.00 BST
Panel: To New Horizons – Building Your Overseas Presence
Speaker: Jack O’Meara – CEO & Co-Founder Ochre Bio

Register for the event here

RNA and the future of medicine
Location: McGill University, Montreal Canada

Date/Time: June 2, 10.10 EDT
Session: The emerging RNA Industry and its ethical challenges
Speaker: Dr. Quin Wills - CSO & Co-Founder, Ochre Bio

Register for the event here

About Ochre Bio
Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases. Using a combination of deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for important liver health challenges, from increasing donor liver supply to reducing cirrhosis complications. Visit: www.ochre-bio.com.

Contacts

Media: Jessica Smith | jessica@somx.co.uk

Industry:

Ochre Bio

Release Versions
English

Contacts

Media: Jessica Smith | jessica@somx.co.uk

Social Media Profiles
Ochre Bio
Ochre Bio
More News From Ochre Bio

GSK Enters Into a Multi-Year Data Licence Agreement With Ochre Bio to Further Investigate the Drivers of Liver Disease

OXFORD, England--(BUSINESS WIRE)--Ochre Bio, a pioneer in chronic liver disease medicine development, has today announced the start of a multi-year data licence agreement with GSK. The partnership will provide GSK with access to Ochre Bio’s computational biology, cellular and perfused human organ platforms to generate proprietary human liver datasets and non-exclusive access to their extensive library of historical liver data. The collaboration will enable Ochre Bio and GSK to deepen the unders...

Ochre Bio announces partnership with Boehringer Ingelheim to develop novel regenerative treatments for patients with advanced liver disease

OXFORD, England--(BUSINESS WIRE)--Ochre Bio announces partnership with Boehringer Ingelheim to develop novel regenerative treatments for patients with advanced liver disease...

Ochre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors

OXFORD, England--(BUSINESS WIRE)--Ochre Bio, an innovator in chronic liver disease medicine development, today announced the appointment of Eliot Forster, Ph.D. as Chairperson of the Board of Directors. With decades of experience in pharmaceutical and biotechnology industries, cofounding and leading several companies Dr. Forster has successfully raised more than $550M in equity financing, having previously served as CEO at F-Star Therapeutics CEO and Immunocore Ltd and Chairperson of Avacta PLC...
Back to Newsroom